<DOC>
	<DOC>NCT02885441</DOC>
	<brief_summary>Patients with acute pancreatitis will be randomly assigned in either study group to receive oral Ketorolac or control group (double blind study).</brief_summary>
	<brief_title>Treatment of Acute Pancreatitis With Ketorolac</brief_title>
	<detailed_description>Patients with acute pancreatitis will be randomly assigned in either study group or control group (double blind study). - The study group will receive oral Ketorolac - The control group will receive a placebo Ketorolac is administrated three times daily by mouth starting from the time of admission for the first three days of hospitalization (72 hours). Hs-CRP will be measured in admission in addition to standard laboratory tests.It will be done every day for up to 5 days, after the administration of study drug or till the time of discharge whichever occurs earlier. Patients will follow up for organ failure involvement and duration of hospitalization. The study will continue to gather clinical follow up information up to four months.</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>1. Predicted Severe Acute Pancreatitis 2. Enrollment within 72 hours of diagnosis 3. Obtaining informed consent 4. Age &gt;18 years 1. Heart disease, Hypertension 2. Hemorrhagic diathesis, Incomplete hemostasis, High risk of bleeding 3. Lactating women 4. Pregnancy 5. Advanced renal disease 6. Hypersensitivity to ketorolac, aspirin, other NSAIDs 7. Concurrent use with aspirin, other NSAIDs, probenecid, or pentoxifylline 8. Active or history of peptic ulcer disease 9. Recent or history of GI bleeding or perforation 10. Inflammatory bowel disease 11. Severe hepatic impairment or active hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Inflammation</keyword>
</DOC>